{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:10Z","timestamp":1793242270724,"version":"4.5.0"},"reference-count":8,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>This Viewpoint describes the advantages of measuring a lipid panel before cardiac catheterization to optimize lipid-lowering therapy.<\/jats:p>","DOI":"10.1001\/jamacardio.2023.1287","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T15:02:42Z","timestamp":1686150162000},"page":"629","source":"Crossref","is-referenced-by-count":2,"title":["The Case for Inclusion of a Lipid Panel in the Standard Precatheterization Laboratory Blood Draw\u2014Stating What Should Be Obvious"],"prefix":"10.1001","volume":"8","author":[{"given":"Lauren S.","family":"Ranard","sequence":"first","affiliation":[{"name":"Division of Cardiology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamon Y.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay J.","family":"Kirtane","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Columbia University Irving Medical Center, New York, New York"},{"name":"Cardiovascular Research Foundation, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"hvp230002r1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ccd.v98.2","article-title":"SCAI expert consensus update on best practices in the cardiac catheterization laboratory: this statement was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) in April 2021.","volume":"98","author":"Naidu","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"issue":"18","key":"hvp230002r2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the US.","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hvp230002r3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008861","article-title":"Lipid-lowering therapy use and intensification among United States veterans following myocardial infarction or coronary revascularization between 2015 and 2019.","volume":"15","author":"Zheutlin","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"hvp230002r4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12872-020-01616-9","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.","volume":"20","author":"Kristensen","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"13","key":"hvp230002r5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1001\/jama.2023.2487","article-title":"Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial.","volume":"329","author":"Hong","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"hvp230002r6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"9","key":"hvp230002r7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019331","article-title":"Adoption of PCSK9 inhibitors among patients with atherosclerotic disease.","volume":"10","author":"Dayoub","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"hvp230002r8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.011464","article-title":"Treatment gaps in guideline-directed medical therapy for patients undergoing higher-risk percutaneous coronary intervention.","volume":"15","author":"Cheng","year":"2022","journal-title":"Circ Cardiovasc Interv"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2805947\/jamacardiology_ranard_2023_vp_230002_1688580074.60782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T15:03:44Z","timestamp":1689174224000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2805947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.1287","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}